At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
TAK-935 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-935 and Placebo for Healthy Volunteer. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-935 with single ascending doses (Part 1) and multiple doses with titration (Part 2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartAug 13, 2020
Primary CompletionNov 14, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.0 years ago
Interventions
TAK-935drug
TAK-935 Tablets
Placebodrug
TAK-935 placebo-matching tablets